ConductScience.org, home
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
API referenceFor AI assistants

Trial · NCT02257567

Participant flow44

How many started, completed or left each group, period by period.

1 to 20 of 44

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDCohort 1a (Phase Ib Safety Run-In): Pola+BR in FL6
Overall StudySTARTEDCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL6
Overall StudySTARTEDCohort 1b (Phase Ib Safety Run-In): Pola+BG in FL6
Overall StudySTARTEDCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL6
Overall StudySTARTEDArm A (Phase II Randomization): Pola+BR in FL39
Overall StudySTARTEDArm B (Phase II Randomization): BR in FL41
Overall StudySTARTEDArm C (Phase II Randomization): Pola+BR in DLBCL40
Overall StudySTARTEDArm D (Phase II Randomization): BR in DLBCL40
Overall StudySTARTEDArm E (Phase II Expansion): Pola+BG in FL20
Overall StudySTARTEDArm F (Phase II Expansion): Pola+BG in DLBCL21
Overall StudySTARTEDArm G+H (Phase II NF Cohort): Pola+BR in DLBCL106
Overall StudySafety PopulationCohort 1a (Phase Ib Safety Run-In): Pola+BR in FL6
Overall StudySafety PopulationCohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL6
Overall StudySafety PopulationCohort 1b (Phase Ib Safety Run-In): Pola+BG in FL6
Overall StudySafety PopulationCohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL6
Overall StudySafety PopulationArm A (Phase II Randomization): Pola+BR in FL38
Overall StudySafety PopulationArm B (Phase II Randomization): BR in FL41
Overall StudySafety PopulationArm C (Phase II Randomization): Pola+BR in DLBCL39
Overall StudySafety PopulationArm D (Phase II Randomization): BR in DLBCL39
Overall StudySafety PopulationArm E (Phase II Expansion): Pola+BG in FL20

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02257567/flow

API referenceFor AI assistants